FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955742389> ?p ?o ?g. }

• W2955742389 abstract "Background. Metastatic colorectal cancer (CRC) remains mostly incurable, with a survival of about two years only. It has been recently proved that CRCs with genetic defects in the mismatch-repair pathway (MMRd), occurring in 15% of early CRC but only in 5% of metastatic CRC, present with a high tumor mutational burden (TMB), which results in an increased number of neoantigens that can be recognized by the immune system. Indeed, treatment with the anti-programmed cell death protein 1 (PD-1) immune checkpoint inhibitor pembrolizumab or nivolumab is effective in inducing durable objective responses in metastatic CRC MMRd cases. These results are quite remarkable considering that the clinical efficacy was independent from RAS mutations, which constrain the use of targeted treatments and negatively affect prognosis. We recently showed in preclinical models that the pharmacological treatment with temozolomide (TMZ) can induce the inactivation of MMR genes and consequently trigger an increase in immunogenic neoantigens. This suggests that TMZ could be used to prime MMR proficient (MMRp) tumors for response to checkpoint inhibitors. Accordingly, mCRC patients recruited in previous clinical trials where TMZ was administered, acquired alterations of MMR genes upon treatment and showed remarkable increase in TMB at disease progression (PD). We thus designed the ARETHUSA clinical trial to test whether a priming course with TMZ in patients can sensitize mCRC to the anti-PD1 inhibitor pembrolizumab. Methods. Arethusa is a 2-cohorts, phase II trial consisting of three different phases (NCT03519412). During screening-phase, 344 mCRC patients with RAS-extended mutations who failed standard therapies will be tested for MMR status. MMRd CRC patients will proceed directly to trial-phase for immediate pembrolizumab treatment (expected N=14). MMR-proficient (MMRp) patients will be further tested for TMZ sensitivity via assessment of expression of O6-methylguanine-DNA methyltransferase (MGMT) by immunohistochemistry and by promoter methylation analysis. Expected 67 IHC-negative, promoter methylation-positive MMRp patients will thus be eligible for priming-phase and will receive TMZ until PD; TMB will then be assessed on tumor biopsies at resistance. Those patients that will have >20 mutations/megabase (expected N=20) will proceed to that trial-phase and will be treated with pembrolizumab. Overall response rate (primary outcome), Progression Free, and Overall Survival, and treatment related toxicities (secondary outcomes) in MMRp pembrolizumab-treated patients will be estimated. Treatment efficacy and toxicity within pembrolizumab-treated MMRd cohort will be used for comparison. Pre- and post-TMZ biopsies and longitudinal blood and stool collection during priming and trial phases will allow for discovery of predictive molecular markers and for the assessment of integrated tumor and (immune)environment evolution in response to therapy. Citation Format: Silvia Marsoni, Giovanni Germano, Andrea Sartore Bianchi, Filippo Pietrantonio, Nicola Personeni, Alessio Amatu, Emanuela Bonoldi, Emanuele Valtorta, Ludovic Barault, Federica Di Nicolantonio, Filippo de Braud, Lorenza Rimassa, Armando Santoro, Silvia Ghezzi, Andrea Cassingena, Giovanna Marrapese, Loredana Lupica, Giulia Siravegna, Giuseppe Rospo, Cosimo Martino, Luca Lazzari, Paolo Luraghi, Nabil Amirouchene-Angelozzi, Alberto Bardelli, Salvatore Siena. Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT215." @default.
• W2955742389 created "2019-07-12" @default.
• W2955742389 creator A5000866932 @default.
• W2955742389 creator A5002545822 @default.
• W2955742389 creator A5002836937 @default.
• W2955742389 creator A5003553378 @default.
• W2955742389 creator A5006266882 @default.
• W2955742389 creator A5009935310 @default.
• W2955742389 creator A5024586369 @default.
• W2955742389 creator A5028593479 @default.
• W2955742389 creator A5031031537 @default.
• W2955742389 creator A5031332948 @default.
• W2955742389 creator A5032586288 @default.
• W2955742389 creator A5034278780 @default.
• W2955742389 creator A5037560184 @default.
• W2955742389 creator A5057184578 @default.
• W2955742389 creator A5059373658 @default.
• W2955742389 creator A5064011158 @default.
• W2955742389 creator A5065803904 @default.
• W2955742389 creator A5070323284 @default.
• W2955742389 creator A5073067170 @default.
• W2955742389 creator A5079437223 @default.
• W2955742389 creator A5080135856 @default.
• W2955742389 creator A5080269874 @default.
• W2955742389 creator A5082045927 @default.
• W2955742389 creator A5089852748 @default.
• W2955742389 creator A5090926458 @default.
• W2955742389 date "2019-07-01" @default.
• W2955742389 modified "2023-10-17" @default.
• W2955742389 title "Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer" @default.
• W2955742389 doi "https://doi.org/10.1158/1538-7445.sabcs18-ct215" @default.
• W2955742389 hasPublicationYear "2019" @default.
• W2955742389 type Work @default.
• W2955742389 sameAs 2955742389 @default.
• W2955742389 citedByCount "0" @default.
• W2955742389 crossrefType "proceedings-article" @default.
• W2955742389 hasAuthorship W2955742389A5000866932 @default.
• W2955742389 hasAuthorship W2955742389A5002545822 @default.
• W2955742389 hasAuthorship W2955742389A5002836937 @default.
• W2955742389 hasAuthorship W2955742389A5003553378 @default.
• W2955742389 hasAuthorship W2955742389A5006266882 @default.
• W2955742389 hasAuthorship W2955742389A5009935310 @default.
• W2955742389 hasAuthorship W2955742389A5024586369 @default.
• W2955742389 hasAuthorship W2955742389A5028593479 @default.
• W2955742389 hasAuthorship W2955742389A5031031537 @default.
• W2955742389 hasAuthorship W2955742389A5031332948 @default.
• W2955742389 hasAuthorship W2955742389A5032586288 @default.
• W2955742389 hasAuthorship W2955742389A5034278780 @default.
• W2955742389 hasAuthorship W2955742389A5037560184 @default.
• W2955742389 hasAuthorship W2955742389A5057184578 @default.
• W2955742389 hasAuthorship W2955742389A5059373658 @default.
• W2955742389 hasAuthorship W2955742389A5064011158 @default.
• W2955742389 hasAuthorship W2955742389A5065803904 @default.
• W2955742389 hasAuthorship W2955742389A5070323284 @default.
• W2955742389 hasAuthorship W2955742389A5073067170 @default.
• W2955742389 hasAuthorship W2955742389A5079437223 @default.
• W2955742389 hasAuthorship W2955742389A5080135856 @default.
• W2955742389 hasAuthorship W2955742389A5080269874 @default.
• W2955742389 hasAuthorship W2955742389A5082045927 @default.
• W2955742389 hasAuthorship W2955742389A5089852748 @default.
• W2955742389 hasAuthorship W2955742389A5090926458 @default.
• W2955742389 hasConcept C121608353 @default.
• W2955742389 hasConcept C126322002 @default.
• W2955742389 hasConcept C143998085 @default.
• W2955742389 hasConcept C2776694085 @default.
• W2955742389 hasConcept C2777389519 @default.
• W2955742389 hasConcept C2777701055 @default.
• W2955742389 hasConcept C2780030458 @default.
• W2955742389 hasConcept C2780057760 @default.
• W2955742389 hasConcept C502942594 @default.
• W2955742389 hasConcept C526805850 @default.
• W2955742389 hasConcept C535046627 @default.
• W2955742389 hasConcept C60748783 @default.
• W2955742389 hasConcept C71924100 @default.
• W2955742389 hasConceptScore W2955742389C121608353 @default.
• W2955742389 hasConceptScore W2955742389C126322002 @default.
• W2955742389 hasConceptScore W2955742389C143998085 @default.
• W2955742389 hasConceptScore W2955742389C2776694085 @default.
• W2955742389 hasConceptScore W2955742389C2777389519 @default.
• W2955742389 hasConceptScore W2955742389C2777701055 @default.
• W2955742389 hasConceptScore W2955742389C2780030458 @default.
• W2955742389 hasConceptScore W2955742389C2780057760 @default.
• W2955742389 hasConceptScore W2955742389C502942594 @default.
• W2955742389 hasConceptScore W2955742389C526805850 @default.
• W2955742389 hasConceptScore W2955742389C535046627 @default.
• W2955742389 hasConceptScore W2955742389C60748783 @default.
• W2955742389 hasConceptScore W2955742389C71924100 @default.
• W2955742389 hasLocation W29557423891 @default.
• W2955742389 hasOpenAccess W2955742389 @default.
• W2955742389 hasPrimaryLocation W29557423891 @default.
• W2955742389 hasRelatedWork W1976397158 @default.
• W2955742389 hasRelatedWork W2124033094 @default.
• W2955742389 hasRelatedWork W2133523341 @default.
• W2955742389 hasRelatedWork W2265625172 @default.
• W2955742389 hasRelatedWork W2396187834 @default.
• W2955742389 hasRelatedWork W2592880717 @default.
• W2955742389 hasRelatedWork W2606812172 @default.
• W2955742389 hasRelatedWork W2746072457 @default.
• W2955742389 hasRelatedWork W2747856781 @default.
• W2955742389 hasRelatedWork W2787838773 @default.

• next